Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QLGN 
Qualigen Therapeutics Inc (QLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: QLGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.16% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.09M USD | Price to earnings Ratio 0.29 | 1Y Target Price 5 |
Price to earnings Ratio 0.29 | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta -0.17 | 52 Weeks Range 1.61 - 10.45 | Updated Date 08/29/2025 |
52 Weeks Range 1.61 - 10.45 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-18 | When - | Estimate - | Actual -1.0019 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -171.67% | Return on Equity (TTM) -841.66% |
Valuation
Trailing PE 0.29 | Forward PE - | Enterprise Value 9160861 | Price to Sales(TTM) 0.39 |
Enterprise Value 9160861 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA -0.05 | Shares Outstanding 1695450 | Shares Floating 1695009 |
Shares Outstanding 1695450 | Shares Floating 1695009 | ||
Percent Insiders 2.17 | Percent Institutions 0.72 |
Upturn AI SWOT
Qualigen Therapeutics Inc
Company Overview
History and Background
Qualigen Therapeutics, Inc. (QLGN) was founded in 1996 as Signal Genetics. It focuses on developing therapeutics with potential for addressing unmet medical needs.
Core Business Areas
- Therapeutics: Developing novel therapeutic candidates for cancer and infectious diseases. This includes AS1411 (QL-S025) and other pre-clinical assets.
- Diagnostics: Previously focused on diagnostic products, but the company has pivoted to therapeutics.
Leadership and Structure
Michael Poirier is the Chairman, President, and CEO. The company has a typical corporate structure with a board of directors and various departments focused on R&D, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- AS1411 (QL-S025): An investigational quadraplex DNA therapeutic targeting cancer and infectious diseases. It is in pre-clinical development. Market share data is not applicable as it is not yet approved. Competitors are companies developing similar therapeutics, such as aptamer-based drugs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in R&D for new therapeutics. The market for cancer and infectious disease treatments is substantial and growing.
Positioning
Qualigen Therapeutics is a small, development-stage company focusing on niche therapeutic areas. Its competitive advantage depends on successful clinical development and regulatory approval of its drug candidates.
Total Addressable Market (TAM)
The TAM for oncology and infectious disease therapeutics is in the billions of dollars. Qualigen is positioned to capture a small fraction of this market if its pipeline products are successful.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with AS1411 (QL-S025)
- Experienced leadership team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Inability to secure funding
Competitors and Market Share
Key Competitors
- GILD
- MRK
- PFE
Competitive Landscape
Qualigen is significantly smaller than its competitors, posing a challenge in the pharmaceutical market. Its strength lies in its unique therapeutic approach but has disadvantages in financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is driven by advancements in the pre-clinical pipeline and funding acquisitions.
Future Projections: Future growth depends heavily on the successful development and commercialization of AS1411 (QL-S025) and other pipeline candidates. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing AS1411 (QL-S025) through pre-clinical studies and seeking partnerships.
Summary
Qualigen Therapeutics is a small, high-risk, high-reward development-stage company focused on novel therapeutics. Its success hinges on the progression of AS1411 (QL-S025) and other pipeline products through clinical trials. Funding and partnerships are crucial for its growth, while clinical trial failures and competition pose significant risks. The company needs to secure more funding to propel its pipeline through trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Qualigen Therapeutics Inc. SEC Filings
- Company Press Releases
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qualigen Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2015-06-24 | Interim CEO, Interim CFO, Chief Accounting Officer & Chairman of the Board Mr. Kevin A. Richardson II | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://qlgntx.com |
Full time employees - | Website https://qlgntx.com | ||
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.